跳至主要内容
临床试验/CTRI/2017/04/008282
CTRI/2017/04/008282已完成3 期

A Comparative study of Shwasahara Dashemani in the Management of Tamaka Shwasa(Bronchial Asthma)in Children-A randomized open label clinical Trail

Director IPGT and RA GAU JAMNAGAR1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年10月4日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
relieve in the sign and symptom of shwasa roga or Bronchial asthma

研究概览

简要总结

Present clinical trial is randomised clinical trail on Tamaka Shwsa (Bronchial Asthma) in children of either sex between 2 to 12 years of age. Study will evaluate the role of Shwasahara Dashemani Avaleha from caraka samhita sutra sthan and Shwasahara Dashemani churna from caraka samhita sutra sthan. Intervational drug is Shwasahara Dashemani Avaleha while comparator agent is Shwasahara Dashemani churna.

Study is going to be conducted with primary aim to relieve the symptom of childhood asthma

Till date 50 patients are registered in clinical trial

As trial as in progress final conclusion or remarks can be drawn only after the completion of clinical trial

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
2.00 Year(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • Patients of 2 – 12 years of age of either sex.
  • Diagnosed cases of Tamaka Shwasa with at least 2 episodes of asthma symptoms during the previous year.
  • Mild persistent asthmatic patients.
  • Patients on other drug therapy will be included only after completion of wash out period of three weeks.

排除标准

  • Children of age below 2 years and above 12 years.
  • Patients with status asthmatics.
  • Evidence of active Concomitant Pulmonary Diseases other than asthma.
  • Evidence of requirement of intubations for asthma, or had been hospitalized for asthma within one month before, Unresolved Sinus Disease or an unresolved upper or lower respiratory tract infection within 2 weeks.
  • Concomitant severe systemic disease (cardiovascular, renal, hepatic, endocrine, haematological, neurologicaletc.).

结局指标

主要结局

relieve in the sign and symptom of shwasa roga or Bronchial asthma

时间窗: Drug trail time 6 weeks | Follow up time 8 weeks

次要结局

  • To prevent the recurrence of attack of breathlessness(To increase the immunity against allergens)

研究者

发起方
Director IPGT and RA GAU JAMNAGAR
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验